The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I substance in the United States, meaning the only legal access pathways are through active...
Ketamine vs. esketamine (Spravato) is one of the most common points of confusion for people exploring treatment-resistant depression options. Both work through a similar mechanism in the brain, but they differ in molecular composition, route of administration, FDA...
Couples psychedelic therapy is an emerging clinical area with early but substantive evidence behind it. Professionally supported shared experiences using MDMA or psilocybin can reduce relational rigidity, improve communication, and address post-trauma dynamics. They...
Research into psilocybin aging effects is accelerating, with preclinical studies pointing to neuroplasticity promotion, reduced neuroinflammation, and improvements in longevity biomarkers. The findings are genuinely interesting, but human data remains limited, and...
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame the conversation, what questions to bring, and what to understand about medications like SSRIs before you book that...
5-MeO-DMT therapy is attracting serious interest from researchers, executives, and people seeking relief from depression, anxiety, and trauma. The compound is potent, fast-acting, and increasingly the subject of clinical investigation. It also carries real risks that...
